Azafaros | ANPDF

Community News and Events

Welcome to the ANPDF blog, where we share the latest updates, stories, and breakthroughs in the fight against Niemann-Pick Disease. Join us as we raise awareness, support families, and drive research forward.

Jump to the NP-C Corner by Ellie

Search for an article or browse by topic below.

Search

Azafaros Community Update | January 9, 2025

Exciting Advances in Azafaros Clinical Programs for NPC and GM Gangliosidoses Azafaros has announced significant progress toward global...

ANPDF

Jan 10, 20251 min read

Azafaros Community Update | December 20, 2024

Exciting Advances in Azafaros Clinical Programs for NPC and GM Gangliosidoses Today, Azafaros shared an important update about their...

ANPDF

Dec 20, 20241 min read

Azafaros Media Release | July 16, 2024

Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C Read the...

ANPDF

Jul 17, 20241 min read

Azafaros Media Release | March 12, 2024

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients.

ANPDF

Mar 14, 20241 min read

Azafaros Media Release | December 11, 2023

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled Read the full statement from...

ANPDF

Dec 21, 20231 min read

Azafaros Media Releases | January 5-9, 2023

"Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102" Read the press release from January 5, 2023...

ANPDF

Jan 10, 20231 min read

Community News and Events

Topics

Azafaros Community Update | January 9, 2025

Azafaros Community Update | December 20, 2024

Azafaros Media Release | July 16, 2024

Azafaros Media Release | March 12, 2024

Azafaros Media Release | December 11, 2023

Azafaros Media Releases | January 5-9, 2023